Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights

Investor logo

Warning

This publication doesn't include Faculty of Arts. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

KRAL Michal DAS Amiyaranjan KOTACKA Tomas BLAHOSOVA Anna LISCAKOVA Veronika HODEK Jan KONVALINKA Jan DEMO Gabriel KOZISEK Milan

Year of publication 2025
Type Article in Periodical
Magazine / Source ACS Infectious Diseases
MU Faculty or unit

Central European Institute of Technology

Citation
web https://pubs.acs.org/doi/10.1021/acsinfecdis.5c00832
Doi https://doi.org/10.1021/acsinfecdis.5c00832
Keywords Rift Valley fever virus; L protein; antivirals; polymerase inhibitors; resistance mutations; structural insights
Attached files
Description Rift Valley fever virus (RVFV) is an arbovirus from the Phenuiviridae family that can cause severe disease in humans and livestock, with outbreaks resulting in substantial economic losses. Despite the availability of attenuated vaccines for animals, there is no approved preventive or therapeutic agent for human RVFV infections. Moreover, the safety and efficacy of the current veterinary vaccines remain uncertain. The RVFV L protein, a 250 kDa polymerase, plays a key role in viral replication and transcription, containing endonuclease, RNA-dependent RNA polymerase (RdRp), and cap-binding domains. Structurally conserved across related viruses and functionally analogous to the influenza virus polymerase, the L protein is a compelling antiviral target. In our study, we screened a library of polymerase inhibitors and identified several compounds with inhibitory activity against the RVFV polymerase. We validated their effect using both live virus assays and a minigenome luciferase reporter system. Resistance mutants were generated, and key mutations conferring resistance to the inhibitors were identified and characterized. Some of these key mutations were structurally analyzed via cryo-electron microscopy, using a new structure of the apo form of wild-type RVFV L protein resolved at 3.5 & Aring;. This structure provides critical insights into how the mutations can influence inhibitor binding and RVFV polymerase function. These findings provide insight into how these mutations may confer resistance by affecting inhibitor binding and polymerase activity.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.